semaglutide cardiovascular outcomes study 2025 news 2.4 mg delivered a statistically significant 20% risk reduction in major adverse events – REGENHEALTHSOLUTIONS (RHS) Oral Semaglutide Reduces Cardiovascular Events

That feels wild that pharmacies are selling variations of drugs that arent even on the market

Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, non-insulin-treated type 2 diabetes: results from the Structured Testing Program study

In preclinical and clinical research models, this has translated into effects on energy expenditure, hepatic lipid metabolism, and body composition that go beyond what dual agonists alone have demonstrated

The k red value of 1.4 10 6 M 1 s 1 for PfGrx C88S (SH) 2 is about two orders of magnitude higher than the highest k ox value for PfGrx C32S/C88S (SSG) in accordance with a physiological relevance of glutaredoxins as deglutathionylating enzymes